Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
ViiV Healthcare Company et al v. Gilead Sciences, Inc.
Case Number:
1:18-cv-00224
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
February 01, 2022
Gilead Pays ViiV $1.25B Plus Royalties To End HIV Patent Suit
Gilead has agreed to pay $1.25 billion plus royalties to GlaxoSmithKline venture ViiV Healthcare to settle claims Gilead infringed patents with its HIV drug, the companies announced Tuesday, a deal that comes less than a month after a trial in the high-profile case was delayed due to COVID-19.
-
January 05, 2022
Omicron Surge Reshuffles Patent Trial Plans Once Again
The beginning of January was shaping up to be a busy time for patent jury trials with judges scheduling several to kick off the new year, following a lull during the pandemic, but skyrocketing viral infections have led many of the trials to be postponed.
-
January 04, 2022
COVID Woes Delay High-Profile Gilead, Samsung IP Trials
Two notable intellectual property trials have been postponed amid the latest COVID-19 surge, with a case against Gilead over HIV drug patents now set to head to trial in May and another claiming Samsung infringed a wireless battery charging patent scheduled to go before a jury next month.
-
December 16, 2021
IP Forecast: Feds To Spar With Gilead Over CEO's Testimony
Gilead Sciences will ask a Delaware federal judge next week to block the federal government from deposing the pharmaceutical company's CEO in a high-profile patent case over allegations Gilead made billions by selling HIV medications using research funded by taxpayers. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.